Grace Therapeutics, Inc., formerly known as Acasti Pharma Inc., has released its financial results for the year ended March 31, 2025. The company reported a net loss from operating activities of $16.679 million, a notable increase from the $12.852 million loss recorded in the previous year. Research and development expenses saw a significant rise to $9.511 million, up from $4.683 million the previous year. General and administrative expenses were reported at $7.168 million, compared to $6.684 million in the prior year. The company also reported a gain of $3.218 million from the change in fair value of derivative warrant liabilities, contrasting with a $2.728 million loss in the previous year. The report did not include specific guidance or outlook for future periods.